Case Report
Copyright ©The Author(s) 2019.
World J Hepatol. Feb 27, 2019; 11(2): 217-225
Published online Feb 27, 2019. doi: 10.4254/wjh.v11.i2.217
Table 1 Laboratory values, Child-Pugh class, model for end-stage liver disease score and medications given for hepatic encephalopathy of patient 1, 2, and 3 before the transjugular intrahepatic portosystemic shunts placement, before the parallel placement, and 6-mo follow-up
StatusPatient 1Patient 2Patient 3
Before TIPSChild-Pugh B; MELD 11; bilirubin 1.1, INR 1.5, PTT 18.6, albumin 2.6; DV post TIPS: 153 (TIPS), 33 cm/s (MPV). Lactulose 10 g/dChild-Pugh B; MELD 11; bilirubin 0.7, INR 1.3, PTT 16.6, and albumin 3.5. Rifaximin 550 mg × 2/d, Lactulose 20 g × 3/dChild-Pugh C; MELD 12; bilirubin 1.6, INR 1.4, PTT 17.1, and albumin 2.5; DV immediately post-TIPS: 96 (TIPS), 89.5 cm/s (MPV). Rifaximin 550 mg × 2/d, Lactulose 30 g/45 mL × 3/d
Before PSChild-Pugh B; MELD 15; bilirubin 4.6, INR 1.3, PTT 17.0, and albumin 2.5; DV: 155 (TIPS), 18 cm/s (MPV). Rifaximin 550 mg × 2/d Lactulose 10 g/dChild-Pugh B; MELD 10; bilirubin 0.7, INR 1.4, PTT 17.1, and Albumin 2.1; DV 2 wk post-PS: 147 (TIPS), 138 (PS), and 16 cm/s (MPV). Rifaximin 550 mg × 2/d, Lactulose 20 g × 3/dChild-Pugh C; MELD 13; bilirubin 0.7, INR 1.4, PTT 17.1, and Albumin 2.5; DV: 90.9 (TIPS) 37 cm/s (MPV). Rifaximin 550 mg × 2/d, Lactulose (20 g) 30 mL × 3/d, Piperacillin 4.5 g/6 h
6 mo post-PSChild-Pugh B; MELD 21; bilirubin 4.5, INR 1.3, PTT 16.5, and albumin 3.5; DV: 78 (TIPS), 144 (PS), 39.3 cm/s (MPV). Rifaximin 550 mg × 2/d Lactulose 10 g/dChild-Pugh B; MELD 21; bilirubin 2.5, INR 1.5, PTT 18.5, and albumin 2.8; DV: 85.8 (TIPS), 109 (PS), and 83 cm/s (MPV). Rifaximin 550 mg × 2/d, Lactulose 20 g × 3/dChild-Pugh C; MELD 14; bilirubin 2.1, INR 1.3, PTT 16.7, and albumin 2.0; DV: 72 (TIPS), 92 (PS), and 68 (MPV) cm/s. Rifaximin 550 mg × 2/d, Lactulose (20 g) 30 mL × 3/d